cGAS and/or STING deficiency has been reported in multiple tumor types.[23, 28] Notably, > 20% advanced colorectal cancers show complete loss of STING expression,[43] potentially limiting the therapeutic efficacy of STING agonist‐based immunotherapies. This evidence concerns the gene CGAS and colorectal cancer.